Abstract
To the Editor:
We believe that hepatic atrial infusion, new drugs, and biochemical modulation deserve more attention than they received in Dr. Moertel's review of chemotherapy for colorectal cancer (April 21 issue)
1
. With respect to hepatic arterial infusion, two large studies with a crossover design demonstrated survival advantages for patients who were crossed over from systemic to hepatic arterial chemotherapy; two studies in which there was no survival advantage associated with hepatic therapy involved only small numbers of patients
2
. In the study by the National Cancer Institute,
2
the median survival was 22 and 12 months for the groups . . .